Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04562558 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia

StatusActive, Not Recruiting
PhaseNot applicable
Sponsorxiang yang
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 2024 to Nov 11, 2024
    • Site details revised
    v6
  2. Enrollment target: 176 to 228v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  5. Start date: Sep 2020 to Sep 29, 2020v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators conducted a randomized trial to study how well multi-day methotrexate protocol works compared to biweekly single-dose actinomycin D protocol in treating patients with low-risk gestational trophoblastic neoplasia. It is not yet known whether multi-day methotrexate protocol is as effective as biweekly single-dose actinomycin D protocol in treating patients with gestational trophoblastic neoplasia.
Trial Details
NCT Number NCT04562558
Lead Sponsor xiang yang
Conditions
(from sponsor)		 Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor, Stage II Gestational Trophoblastic Tumor, Stage III Gestational Trophoblastic Tumor, Invasive Mole, Choriocarcinoma
Related terms Choriocarcinoma, Gestational Trophoblastic Disease, Hydatidiform Mole, Invasive
Enrollment 228 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov